TROG Cancer Research
Members Login   CQMS Login

Upcoming lung trials

Our clinical trials are focused on the improving treatments and outcomes for people with lung cancer.

TD 17.09 (STIMULI) - The aim of the current study is to investigate the efficacy and tolerability of the standard treatment (chemotherapy and radiotherapy) alone for limited stage SCLC, compared with the standard treatment followed by nivolumab and ipilimumab in patients with limited SCLC.

Primary Sponsor: 
Collaborating group: TROG


TD 17.02 (OUTRUN) - The aim of this study is to compare the effects of Osimertinib alone versus Osimertinib plus Stereotactic Radiosurgery (SRS) on intra-cranial disease control in EGFR mutated NSCLC with brain metastases diagnosed or developed while on first line EGFR tyrosine kinase inhibitors.

Primary sponsor: TROG


TD 17.01 (DESSERT) - This study aims to show that use of a Decision Support System (DSS) will increase the proportion of patients receiving radiotherapy tailored to their individual prognostic profile, improve patient satisfaction with the decision making process and reduce decisional regret after treatment.

Primary sponsor: TROG


TD 13.03 (SABR-OS) - This trial will investigate if Stereotactic Ablative Body Radiotherapy (SABR) is more effective than surgery for early stage Non-Small Cell Lung Cancer (NSCLC) in patients considered at high risk of surgical resection.

Primary sponsor: TROG


 

 

We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.